Validation of French PHQ-4 and PC-PTSD-5 Screening Scales
ConditionMental Illness
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
Mental illness is a major public health issue. It affects one in five people, represents the largest expense for health insurance (14%), is the leading cause of years lived with disability, and suicide is the main cause of death among people aged 15 to 35. Depression affects 15 to 20% of individuals at some point in their lives. Trauma-related disorders affect 4.6% of people, including 1- 2% with post-traumatic stress disorder (PTSD).
Screening for mental health problems in primary care is crucial. It enables doctors to provide early treatment, reduces the need for emergency care, and decreases both the number and duration of hospital stays. However, general practitioners and other non-mental health professionals often report lacking the time, training, and tools to conduct such screenings. Fortunately, brief and validated screening tools exist in English: The PHQ-4 (Patient Health Questionnaire-4) for anxiety and depression, and the PC-PTSD-5 (Primary Care PTSD Screen for DSM-5) for PTSD. So far, no French versions of these tools have been validated.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years,
Outpatient or hospitalized for any health-related reason,
Oral and written proficiency in French,
Patient informed and willing to participate in the study,
Disqualifiers
Individuals under legal protection measures (guardianship, conservatorship, or legal supervision),
Other factors preventing obtaining non-opposition or conducting the research, such as: limited French proficiency, hearing impairment, or significant cognitive disorders
Trial population
This study will involve adult patients, regardless of sex, who present for consultation.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Assess the validity of the French version of the PHQ-4 (Patient Health Questionnaire-4 ) scale
This scale is used for the screening of anxiety and depression. The scale will be scored. Score ranging from 0 to 12, corresponding to four levels of psychological distress: * None: 0-2 * Mild: 3-5 * Moderate: 6-8 * Severe: 9-12 Patients will complete this scale at Visit 1 and Visit 2.
Time frame
14 days2
Assess the validity of the French version of the PC-TDSD-5 (Primary Care PTSD Screen for DSM-5) scale
Scale assessing whether the patient has experienced unusually or particularly frightening, horrible, or traumatic events. Examples include: * A serious accident or fire * Physical or sexual assault, or sexual abuse * An earthquake or flood * War * Witnessing a person being killed or seriously injured * The death of a close person by homicide or suicide Total score = sum of "YES" responses to questions 1 through 5. Patients will complete this scale at Visit 1 and Visit 2.
Time frame
14 daysSecondary outcomes
1
Assess the feasibility of this screening tool during the first evaluation visit.
The time required for the patient to complete each scale (individually) will be timed and recorded (without informing the patient in order to avoid potential stress).
Time frame
At Visit 1 (at inclusion)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov